Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 82 of 1215 for:    "Hodgkin lymphoma"

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03580564
Recruitment Status : Not yet recruiting
First Posted : July 9, 2018
Last Update Posted : July 9, 2018
Sponsor:
Information provided by (Responsible Party):
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Brief Summary:
The study is to evaluate the efficacy of BGB-A317 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification

Condition or disease Intervention/treatment Phase
Classical Hodgkin Lymphoma Drug: KL-A167 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 104 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
Estimated Study Start Date : July 30, 2018
Estimated Primary Completion Date : February 28, 2021
Estimated Study Completion Date : July 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental
KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Drug: KL-A167
KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)




Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: Up to 2years ]
    Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by IRC per the Lugano Classification


Secondary Outcome Measures :
  1. Progression-free Survival (PFS) [ Time Frame: Up to 2years ]
    From the first dose of KL-A167 to the date of PD or death, whichever occurs first

  2. Duration of Response (DOR) [ Time Frame: Up to 2years ]
    From the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first

  3. Overall Survival (OS) [ Time Frame: Up to 2years ]
    From the first dose of KL-A167 to the date of death

  4. Time to Response [ Time Frame: Up to 2years ]
    From the date of the first dose of KL-A167 to the time the response criteria are first met



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years and older
  • Histopathological confirmed classical Hodgkin's lymphoma
  • Relapsed/refractory cHL include:subject with no response to or with progression after ASCT ;subject which failed failed second line and above chemtherapy;subject which didn't achieve PR after 2 cycles or didn't achieve CR after 4 cycles
  • At least one measurable disease (long axis>15 mm and short axis>5 mm,or both axis>10 mm)
  • ECOG performance status of 0 or 12
  • Subject must have adequate organ functions and meet requirements on laboratory values.:Count of Blood Cells: absolute neutrophil count (ANC) ≥ 1.0 × 109 / L; platelet count (PLT) ≥ 50 × 109 / L; hemoglobin content (HGB) ≥ 7.0 g / Dl; Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN,with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic metastases or Gilbert's syndrome (total bilirubin ≤ 3 × ULN)Renal function: serum creatinine (Cr) ≤ 1.5 × ULN or Creatinine clearance rate(CCR)≥50 mL/min;International normalized ratio (INR) ≤ 1.5 x ULN ;Thyroid function: thyroid stimulating hormone (TSH) in normal range.
  • Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy (including Chinese herbal medicine and Chinese patent medicine) used to control cancer including locoregional treatment must have been completed ≥ 4 weeks before the first dose of KL-A167(Mitomycin or nitroso must have been completed ≥ 6 weeks), and all treatment-related adverse events (except alopecia) are stable and have either returned to baseline or Grade 0/1
  • Subjects of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study medication
  • Subject has voluntarily agreed to participate by giving written informed consent.

Exclusion Criteria:

  • Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma.
  • Known central nervous system lymphoma.
  • Prior malignancy except for curatively treated carcinoma in situ of the cervix or breast ,Superficial bladder cancer,and Squamous cell carcinoma in situ
  • History of severe hypersensitivity reaction to monoclonal antibodies
  • Prior exposure to any anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody.
  • need the other anticancer therapy during the study
  • Received any anticancer vaccine or other medications for immunomodulatory receptor preparations
  • Received HSCT
  • Received ASCT in the past 3 months
  • Serious acute or chronic infection requiring systemic therapy.
  • Subject with active autoimmune disease or history of autoimmune disease with high risk of recurrence.
  • Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily Prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of KL-A167
  • serious medical diseases, ex Suffering from heart failure (New York Heart Association standard III or IV), ischemic heart disease (such as myocardial infarction or angina), congestive heart failure and other cardiovascular diseases, uncontrolled diabetes(fasting blood glucose≥10 mmol/L), uncontrolled high blood pressure(Systolic> 150 mmHg and / or diastolic> 100 mmHg), LVEF<50%
  • QTcF>450 msec
  • Known active HBV or HCV infection.
  • Known HIV infection.
  • Has history of interstitial lung disease or non-infectious pneumonitis. Subjects with prior drug-induced or radiation-induced pneumonitis who are asymptomatic are eligible.
  • Known active pulmonary tuberculosis
  • Has history of AE related with immune system during the Immunotherapy
  • Received a live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.
  • Known neurological or psychiatric diseases
  • Ongoing alcohol or drug abuse
  • Pregnancy (absence to be confirmed by serum β-human chorionic gonadotropin test) or breastfeeding
  • Participation in another clinical trial within the past 4 weeks
  • Other significant disease that in the investigator's opinion should exclude the subject from the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03580564


Contacts
Layout table for location contacts
Contact: Dawei Wu 010-87788268 wumingshi-117@163.com

Sponsors and Collaborators
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Layout table for additonal information
Responsible Party: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
ClinicalTrials.gov Identifier: NCT03580564     History of Changes
Other Study ID Numbers: KL167-Ⅱ-03-CTP
First Posted: July 9, 2018    Key Record Dates
Last Update Posted: July 9, 2018
Last Verified: June 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases